NCT03466671View on ClinicalTrials.gov

A Trial of TTA-121 on Autism Spectrum Disorder

PHASE2UnknownINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

March 30, 2020

Conditions
Autism Spectrum Disorder
Interventions
DRUG

TTA-121

A nove intranasal spray of oxytocin and placebo

Trial Locations (1)

431-3192

Hamamatsu University School of Medicine, Hamamatsu

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Hamamatsu University

OTHER